Description
Product Characteristics: Anti-CIITA antibody detects CIITA. The transactivator CIITA regulates basal and interferon-induced expression of Major Histocompatibility Complex class II genes. CIITA restores expression of all MHC class II gene expression in mutant cells and corrects regulatory defects of MHC class II genes. Antibodies to this transactivator are useful in the study of diseases of pathological MHC class II expression. Antigen can be obtained from Raji cell lysates. Typically levels of CIITA expression are too low to detect endogenous levels of protein expression. Transiently transfected cells are usually employed to study this transcription factor.
Synonyms: MHC class II transactivator type III antibody, MHC2TA antibody, NLR family acid domain containing antibody, NLRA antibody, Nucleotide binding oligomerization domain leucine rich repeat and acid domain containing antibody
Target Information: This gene encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the 'master control factor' for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction. [provided by RefSeq, Jul 2008]